Recent advances in immunotherapy for human glioma

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 631-636

  Carpentier, Antoine F ^a,b   Meng, Yuxia ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Cancer; Glioblastoma; Glioma; Immunotherapy; Vaccine

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; DENDRITIC CELL VACCINE; EPHRIN A2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; PEPTIDE DERIVATIVE; PICIBANIL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX11; TRANSFORMING GROWTH FACTOR BETA ANTISENSE OLIGONUCLEOTIDE; TUMOR ELUTING PEPTIDE; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CLINICAL TRIAL; DENDRITIC CELL; DRUG RESPONSE; GLIOMA; HUMAN; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MYELOID SUPPRESSOR CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; TUMOR CELL DESTRUCTION; TUMOR ESCAPE; TUMOR LYSATE; TUMOR REJECTION;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 33748889305     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245321.34658.f4     Document Type: Review

References (55)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
2. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-1368.
3. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588-594.
4. Bucciero A, Vizioli L, Giamundo A, et al. Prognostic significance of lymphoid infiltration in cerebral malignant gliomas. J Neurosurg Sci 1990; 34:145-148.
5. Dietrich PY, Walker PR, Schnuriger V, et al. TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture. Int Immunol 1997; 9:1073-1083.
6. + T cells.
7. Becher B, Prat A, Antel JP. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000; 29:293-304.
8. Aloisi F. Immune function of microglia. Glia 2001; 36:165-179.
9. Watters JJ, Schartner JM, Badie B. Microglia function in brain tumors. J Neurosci Res 2005; 81:447-455.
10. Hussain SF, Yang D, Suki D, et al. Innate immune functions of microglia isolated from human glioma patients. J Transl Med 2006; 4:15. An extensive analysis of microglial cells infiltrating human gliomas, with phenotypic and functional studies.
11. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by cross-presenting APCs. Immunity 2005; 22:175-184. Demonstration that the immunization site is important for the homing back of sensitized lymphocytes.
12. Ausiello CM, Palma C, Maleci A, et al. Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur J Cancer 1991; 27:646-650.
13. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37:1160-1166.
14. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000; 89:251-258.
15. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6:331-337.
16. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-3302. An excellent study with comprehensive analysis of the role of Tregs in glioma immunology.
17. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202:931-939. Macrophages infiltrating tumours are an important mechanism for tumour evasion and impair the therapeutic potential of cancer immunotherapies.
18. Graf MR, Sauer JT, Merchant RE. Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas. J Neurooncol 2005; 73:29-36.
19. Wheeler CJ, Black KL, Liu G, et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 2003; 171:4927-4933.
20. Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005; 11:8304-8311.
21. Badie B, Schartner J, Prabakaran S, et al. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 2001; 120:19-24.
22. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988; 62:665-671.
23. Lillehei KO, Mitchell DH, Johnson SD, et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991; 28:16-23.
24. Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398-404.
25. Kruse CA, Cepeda L, Owens B, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45:77-87.
26. Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24:1861-1871.
27. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000; 6:2209-2218.
28. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999; 45:141-157.
29. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003; 9:3294-3302.
30. Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006; 5:233-247. An interesting review on dendritic cell vaccination, with emphasis on combination of immunotherapy and chemotherapy.
31. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005; 7:717-722.
32. Schmitz M, Wehner R, Stevanovic S, et al. Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. Cancer Lett 2006. [Epub ahead of print]
33. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2:1010-1017.
34. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11:5900-5911. A phase 1 trial with a customized preparation of peptides, with some cases of radiologic responses.
35. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-847.
36. Kobayashi T, Yamanaka R, Homma J, et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(z) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003; 52:632-637.
37. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003; 89:1172-1179.
38. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 2004; 6:236-246.
39. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-4979.
40. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma: a feasibility study. Br J Cancer 2004; 91:1656-1662.
41. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515-5525. A trial in patients with glioblastoma with dendritic cells loaded with eluted peptides, with a study on the potential factors that could impair the vaccine efficacy.
42. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160-4167. A phase 1/2 trial in recurrent glioma, using immature and mature dendritic cells, loaded with tumour lysate.
43. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332-336.
44. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50:337-344.
45. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27:452-459.
46. Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 2003; 64:13-20.
47. Parney IF, Chang LJ, Farr-Jones MA, et al. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol 2006; 78:71-80.
48. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004; 22:4272-4281.
49. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198:569-580.
50. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998; 95:1178-1183.
51. Bogdahn U, Oliushine VE, Parfenov VE, et al. Results of G004, a phase IIb study in recurrent glioblastoma patients with the TGF-b2 targeted compound AP 12009 [abstract]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings, 2006; 24
52. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995.
53. Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neurooncology 2006; 8:60-66. A phase 1 study using for the first time TLR9 agonists within the brain.
54. Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105:1135-1143.
55. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.